- Home
- AMRN vs AVTX Comparison
AMRN vs AVTX Comparison
Compare AMRN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- AVTX
- Stock Information
- Founded
- AMRN 1989
- AVTX 2011
- Country
- AMRN Ireland
- AVTX United States
- Employees
- AMRN N/A
- AVTX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- AVTX Health Care
- Exchange
- AMRN Nasdaq
- AVTX Nasdaq
- Market Cap
- AMRN 338.7M
- AVTX 248.3M
- IPO Year
- AMRN 1993
- AVTX 2015
- Fundamental
- Price
- AMRN $15.66
- AVTX $16.67
- Analyst Decision
- AMRN Strong Sell
- AVTX Strong Buy
- Analyst Count
- AMRN 1
- AVTX 9
- Target Price
- AMRN $12.00
- AVTX $30.14
- AVG Volume (30 Days)
- AMRN 142.0K
- AVTX 364.7K
- Earning Date
- AMRN 10-29-2025
- AVTX 11-07-2025
- Dividend Yield
- AMRN N/A
- AVTX N/A
- EPS Growth
- AMRN N/A
- AVTX N/A
- EPS
- AMRN N/A
- AVTX N/A
- Revenue
- AMRN $226,733,000.00
- AVTX $441,000.00
- Revenue This Year
- AMRN N/A
- AVTX N/A
- Revenue Next Year
- AMRN N/A
- AVTX N/A
- P/E Ratio
- AMRN N/A
- AVTX N/A
- Revenue Growth
- AMRN N/A
- AVTX N/A
- 52 Week Low
- AMRN $7.08
- AVTX $3.39
- 52 Week High
- AMRN $20.90
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- AMRN 31.90
- AVTX 57.36
- Support Level
- AMRN $19.39
- AVTX $16.77
- Resistance Level
- AMRN $20.90
- AVTX $19.01
- Average True Range (ATR)
- AMRN 1.03
- AVTX 1.60
- MACD
- AMRN -0.59
- AVTX -0.05
- Stochastic Oscillator
- AMRN 2.42
- AVTX 54.35
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).